Variantes alélicas *3, *4, *5 y *6 del gen CYP2D6 en una muestra de pacientes cubanos con esquizofrenia

Roblejo Balbuena, Hilda; Marcheco Teruel, Beatríz; Monzón Benítez, Giselle; Marín Padrón, Lilia C; Esperón Álvarez, Antonio A; Collazo Mesa, Teresa; Llerena Ruíz, Adrián.
Rev Cuba Genet Comunit ; 13(1): 44-54, 2020.
Artículo en Español | CUMED | ID: cum-77623

Documentos relacionados

  1. Prevalence of CYP2D6 structural variation in large retrospective study.
  2. Leveraging in Vitro Models for Clinically Relevant Rare <i>CYP2D6</i> Variants in Pharmacogenomics.
  3. Genetic polymorphisms analysis of CYP2D6 in the Uygur population.
  4. [Farmacogenetica in de psychiatrie; de huidige status quo].
  5. How does multiple substrate binding lead to substrate inhibition of CYP2D6 metabolizing dextromethorphan? A theoretical study.
  6. Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.
  7. Mechanistic insights on nsSNPs on binding site of renin and cytochrome P450 proteins: A computational perceptual study for pharmacogenomics evaluation.
  8. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
  9. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
  10. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.